The first telithromycin-resistant Streptococcus pneumoniae isolate in Japan associated with erm(B) and mutations in 23S rRNA and riboprotein L4.

This report presents the case of a patient associated with a Streptococcus pneumoniae isolate that was resistant to a new ketolide antibiotic, telithromycin (minimum inhibitory concentration: 4 microg/ml). The patient, a 61-year-old female with bronchiectasis, was treated with 200-400 mg of clarithromycin daily for 6 years until the isolation of the resistant strain but without prior exposure to telithromycin. The strain was isolated from her sputum but not from the nasopharynx. This isolate carried erm(B) and had mutations in 23S rRNA and riboprotein L4. To our knowledge, this is the first case report concerning a telithromycin-resistant S. pneumoniae isolate in Japan by mutation in L4. Although the long-term clarithromycin administration may have contributed to the induction of resistance in this patient, this could not be confirmed, since S. pneumoniae was not isolated until the present episode.

[1]  P. Huovinen,et al.  Streptococcus pneumoniae Isolates Resistant to Telithromycin , 2006, Antimicrobial Agents and Chemotherapy.

[2]  D. Hoban,et al.  Mechanisms of resistance to telithromycin in Streptococcus pneumoniae. , 2005, The Journal of antimicrobial chemotherapy.

[3]  D. Farrell,et al.  Activities of Telithromycin against 13,874 Streptococcus pneumoniae Isolates Collected between 1999 and 2003 , 2004, Antimicrobial Agents and Chemotherapy.

[4]  S. Amyes,et al.  High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae. , 2003, The Journal of antimicrobial chemotherapy.

[5]  R. Lütticken,et al.  Ribosomal Mutations Conferring Resistance to Macrolides in Streptococcus pneumoniae Clinical Strains Isolated in Germany , 2003, Antimicrobial Agents and Chemotherapy.

[6]  Y. Hirakata,et al.  Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. , 2002, The Journal of antimicrobial chemotherapy.

[7]  R. Leclercq,et al.  Diversity of Ribosomal Mutations Conferring Resistance to Macrolides, Clindamycin, Streptogramin, and Telithromycin in Streptococcus pneumoniae , 2002, Antimicrobial Agents and Chemotherapy.

[8]  M. Jacobs,et al.  Mutations in 23S rRNA and Ribosomal Protein L4 Account for Resistance in Pneumococcal Strains Selected In Vitro by Macrolide Passage , 2000, Antimicrobial Agents and Chemotherapy.

[9]  P. Appelbaum,et al.  In Vitro Development of Resistance to Telithromycin (HMR 3647), Four Macrolides, Clindamycin, and Pristinamycin inStreptococcus pneumoniae , 2000, Antimicrobial Agents and Chemotherapy.

[10]  S. Kudoh,et al.  Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. , 1998, American journal of respiratory and critical care medicine.

[11]  P. Wayne PERFORMANCE STANDARDS FOR ANTIMICROBIAL SUSCEPTIBILITY TESTING, NINTH INFORMATIONAL SUPPLEMENT , 2008 .

[12]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .